Is it safe to give inactivated vaccines such as influenza, COVID‑19, or pneumococcal vaccine to a patient taking nintedanib 150 mg twice daily without stopping the medication?

Nintedanib and Inactivated Vaccines: Safe to Continue Without Interruption

Yes, it is safe to administer inactivated vaccines such as FSME-IMMUN (tick-borne encephalitis vaccine), influenza, COVID-19, or pneumococcal vaccines to patients taking nintedanib 150 mg twice daily without stopping the medication.

Key Recommendation

Nintedanib is a tyrosine kinase inhibitor used for idiopathic pulmonary fibrosis and does not function as a traditional immunosuppressive agent that would require medication adjustment around vaccination. The available evidence does not identify nintedanib among medications requiring dose modification or temporary discontinuation for vaccine administration.

Evidence-Based Rationale

Medications Requiring Adjustment vs. Nintedanib

The most recent guidelines specifically address which immunosuppressive medications require modification around vaccination 1, 2:

• Medications requiring holds: Methotrexate (2 weeks for influenza only), rituximab (timing adjustments), JAK inhibitors (1-2 weeks), and high-dose corticosteroids (≥20 mg prednisone equivalent) 1, 3
• Nintedanib is notably absent from all guideline recommendations regarding medication holds for vaccination

General Principles for Inactivated Vaccines

Multiple guidelines consistently state 4, 5, 2:

• Inactivated vaccines can be administered simultaneously with other inactivated vaccines or at any time before/after without spacing requirements 6
• Inactivated vaccines are generally safe in patients on most therapies, with specific exceptions for highly immunosuppressive regimens
• No timing restrictions exist for inactivated vaccines with most medications unless specifically noted

Nintedanib's Mechanism and Safety Profile

Nintedanib's pharmacology does not suggest immunosuppressive effects that would impair vaccine response:

• Functions as an intracellular tyrosine kinase inhibitor targeting fibrotic pathways 7, 8
• Long-term safety data shows manageable adverse events primarily involving gastrointestinal symptoms (diarrhea) and hepatic function monitoring 8, 9
• No documented interactions with vaccines or immune response impairment in extensive safety databases

Practical Implementation

Proceed with Vaccination

• Administer FSME-IMMUN or any other inactivated vaccine (influenza, COVID-19, pneumococcal) without interrupting nintedanib
• Continue nintedanib 150 mg twice daily on schedule
• No dose adjustment needed before or after vaccination

Standard Monitoring

• Monitor for typical vaccine side effects (injection site reactions, fever, myalgia) 3
• Continue routine nintedanib monitoring (liver enzymes, gastrointestinal symptoms) as per standard care 7, 9
• No additional safety monitoring required specifically for the vaccine-drug interaction

Important Caveats

When to Consider Timing Adjustments

While nintedanib itself doesn't require holds, consider the patient's overall clinical context:

• If on concurrent immunosuppressants: Follow guidelines for those specific agents (e.g., if also taking methotrexate, consider the 2-week hold for influenza vaccination) 1
• If on high-dose corticosteroids (≥20 mg prednisone): May defer non-influenza vaccines until taper below 20 mg daily 1
• Severe acute illness: Defer vaccination until moderate-to-severe illness resolves, but mild illness is not a contraindication 6

Optimal Timing Considerations

Though not required for nintedanib, general best practices suggest:

• Ideally vaccinate 2-4 weeks before starting any new immunosuppressive therapy if treatment hasn't begun 5, 2
• For ongoing nintedanib therapy, vaccinate at any time without interruption
• Ensure up-to-date vaccination status given underlying pulmonary disease increases infection risk

Clinical Bottom Line

Continue nintedanib 150 mg twice daily without interruption when administering FSME-IMMUN or any other inactivated vaccine. The absence of nintedanib from all guideline recommendations for medication adjustment around vaccination, combined with its non-immunosuppressive mechanism of action, supports safe concurrent administration. Focus monitoring on standard vaccine reactions and routine nintedanib safety parameters rather than any specific vaccine-drug interaction concerns.